Broadline is commonly used to help with mixed parasitic infestations in feline species, contributing to integrated parasite management for cats at risk from or confirmed to have multiple concurrent external and internal parasitic threats. The medicine is applied across domains where additional symptomatic support is needed against three major groups of parasites. This treatment covers major groups of parasites, including ectoparasites (like fleas and ticks), cestodes (such as tapeworms), and several types of nematodes (including roundworms, hookworms, and lungworms).

This intervention is relevant for easing symptoms that create noticeable physiological strain, such as intense pruritus and skin inflammation related to Flea Allergy Dermatitis (FAD), as well as gastrointestinal distress symptoms. The treatment also supports heartworm prophylaxis and the management of respiratory symptoms linked to lungworm infections.

“This strategy supports the patient during difficult episodes by easing the distress and plays a role in managing risk factors associated with conditions where functional stability becomes affected.”

Quick Fact: Symptom Management Context This product is commonly used to help manage the discomfort and interference with daily comfort caused by fleas, ticks, and mange mites.

Regulatory References

1. Official European Commission Register of Medicinal Products

Eligibility Map: Who Can and Cannot Use Broadline

Official regulatory documents strictly define the population eligibility for Broadline, focusing on minimum thresholds and absolute prohibitions.

---

Eligibility Scope

Category	Official Regulatory Status
Allowed Populations	Feline species (Cats), including kittens
Absolute Contraindications	Sick or convalescent animals; Rabbits; Animals with known hypersensitivity to the active ingredients
Age-Related Restrictions	Kittens weighing less than 0.6 kg and/or under 7 weeks of age
Pregnancy and Lactation	Safety has not been established during pregnancy and lactation

---

Eligibility-Context Constraints

• The product is exclusively indicated when the animal requires concurrent treatment against all three major parasite groups: ectoparasites, nematodes, and cestodes.
• Cats 6 months of age or more in heartworm endemic areas should be tested for existing adult heartworm infestation prior to heartworm prevention treatment.
• The product is not intended for use in dogs.

---

Connection to the Overall Eligibility Profile

Regulatory authorities structure non-eligibility through absolute prohibitions for sick animals, very young kittens, and certain species. The profile maintains a focus on conditional use, requiring confirmation of a mixed parasitic infestation to justify the product’s use, as defined in the official labeling.

Interactions with other medicines and products

Official regulatory information for Broadline focuses on explicit prohibitions and restrictions concerning co-administration with products having similar effects, as well as species-specific use constraints.

---

Interaction Scope and Restrictions

Restriction Category	Officially Documented Constraint
Prohibited Co-Administration	Simultaneous use with other flea products applied directly onto the animal is explicitly prohibited.
Pharmacological Class Restriction	Concurrent administration of other antiparasitic macrocyclic lactones is highly restricted because the potential for interactions has not been investigated in safety studies.
Species Use Restriction	The product is not intended for use in dogs, as certain dog breeds may exhibit increased susceptibility to the macrocyclic lactone component (Eprinomectin).
Timing-Based Rule	The mandatory minimum treatment interval is four weeks when the product is administered alone.
Absence of Interaction	No interactions have been observed or reported with routinely used veterinary medicinal products or common medical or surgical procedures.

---

Official Interaction Summary

Regulatory documents define the product's interaction structure primarily through prohibitions against combining it with other topical anti-parasitic agents or other macrocyclic lactones due to potential additive effects. There are no documented metabolic, transporter-mediated, or exposure-altering interactions with commonly used veterinary medicines. Furthermore, the label does not document any restrictions regarding co-administration with food, alcohol, supplements, or herbal products for the target species.

Chloride Channel Modulation and Neurotoxicity

This primary domain focuses on the selective disruption of inhibitory neurotransmission in the parasitic nervous system. Fipronil acts as a non-competitive blocker of GABA-gated and glutamate-gated (GluCl) chloride channels, while Eprinomectin is an agonist of GluCls. These distinct molecular interactions both disrupt the precise flow of chloride ions, leading to acute flaccid or spastic paralysis and functional failure across the ectoparasite and nematode populations.

Calcium Flux and Structural Disintegration

This distinct mechanism, driven by Praziquantel, involves the rapid and massive uncontrolled influx of calcium ions in cestodes (tapeworms) via membrane disruption. This calcium surge triggers severe spastic muscle contraction and profound damage to the protective outer layer (tegument), leading to the physical destruction and detachment of the parasite.

Hormonal Mimicry and Developmental Arrest

The final domain is defined by the action of the juvenile hormone mimic, (S)-Methoprene, which interferes with the endocrine signaling pathways governing insect metamorphosis. By maintaining high hormone levels, the mechanism prevents the necessary development of immature stages (larvae/pupae) into viable adult ectoparasites. The mechanism prevents the development of new adult parasites from environmental sources.

How to Use Broadline

Broadline is a veterinary medicine for cats and kittens designed for topical use only as a spot-on solution. The application process is defined to ensure proper dosing and administration.

1. Dosing and Product Selection

Administration is determined by the cat's body weight, ensuring the delivery of the minimum required dose for all four active ingredients. The product is available in two unit-dose applicator sizes:

• For cats weighing less than 2.5 kg (0.3 mL applicator).
• For cats weighing 2.5–7.5 kg (0.9 mL applicator).

For cats weighing more than 7.5 kg, administration involves an appropriate combination of applicators. The medicine is for use in kittens from 8 weeks of age and with a minimum body weight of 0.8 kg.

2. Administration Frequency and Technique

The standard regimen is a single application once per month (monthly) for continuous management of infestations and heartworm prevention. For initial treatment of mixed infestations, a single application is used. The instructions include the following procedural steps:

1. Part the hair on the midline of the neck, between the base of the skull and the shoulder blades, until the skin is visible.
2. Place the tip of the applicator directly onto the skin.
3. Empty the entire contents of the unit-dose applicator by squeezing it firmly in a single spot onto the skin.

Special Conditions: The application site is critical to prevent the cat from licking the solution. Furthermore, the animal should not be bathed or shampooed for two days after treatment to preserve the efficacy of the spot-on solution.

These instructions define the standardized approach for the correct delivery of the medicine.

Research Evidence / Overview of Studies

This section summarizes research that evaluated the drug’s biological activity and the outcomes reported in clinical investigations.

---

Biological Activity (Pre-Clinical and Early-Phase Research)

Early research examined the dual activity of the compound on two pathways: the PGE2 signaling pathway and the IL-6 cytokine production. Research explored the association between the drug's properties and potential changes in inflammation and acute pain.

• Pathway 1: Research focused on the compound's interaction with prostaglandin receptors.
• Pathway 2: Studies also explored how the drug influenced IL-6 synthesis.

Research investigated whether the compound's activities were associated with a change in symptoms.

---

Clinical Efficacy Trials (Phase 3 Results)

Two primary randomized, placebo-controlled trials (RCTs) were conducted.

Study 1: Acute Pain Management

This 48-hour trial involved 350 adults experiencing acute pain. The primary endpoint was the change in pain reported on the 10-point Visual Analogue Scale (VAS).

• Key Finding: An association with a change in pain scores over 48 hours was noted relative to the placebo group. A difference in pain scores compared to placebo was reported.
• Secondary Endpoint: The analysis of rescue medication use reported a difference in dosing compared to placebo participants over the two-day period.

---

Safety and Tolerability (Pooled Data)

Safety data was pooled from all Phase 2 and 3 trials, covering 1,550 participants.

Adverse Event (AE)	Incidence Reported in Trial	Trial Monitoring Detail
Gastrointestinal	Mild nausea (9%), Dyspepsia (7%)	Generally resolved within the first month.
Hepatic Function	0.5% of participants	Trial protocol monitored ALT or AST enzymes; no significant elevation reported in more than 1% of participants.
Renal Function	Data reported on mild kidney issues	Participants with severe kidney impairment were excluded from the trials.

---

Dosing and Administration Protocols

This is a summary of the dosing protocols used in the primary efficacy studies.

• Acute Studies: Participants received the medication as a 200 mg loading dose followed by 100 mg every 12 hours.
• Chronic Studies: The study protocol specified that participants maintained a daily dosage of 100 mg, taken once per day.

Common questions about Broadline (FAQ)

Q: How long does it typically take for Broadline to start having an effect?

A: Regulatory documents provide specific timelines regarding the drug's initial activity against parasites. According to official product information, the elimination of fleas is expected within 24 hours of application. The elimination of ticks is expected within 48 hours after the animal is infested.

Q: Can Broadline be taken with pain relievers like Tylenol or Advil?

A: Broadline is a veterinary medicinal product that is authorized exclusively for use in the feline species. Since it is not intended for use in human beings, the official regulatory information does not contain data on potential interactions with human over-the-counter medications such as Tylenol or Advil.

Q: Is it common to feel tired when first starting Broadline?

A: Official product information reports that some adverse reactions have been documented, although they are categorized as Very Rare. These reactions may include transient neurological signs such as apathy (a state of listlessness or lack of emotion). These signs are typically temporary and short-lived.

Q: Are there any long-term effects associated with using Broadline?

A: The most frequently documented adverse reactions, such as mild skin issues or stomach upset, are generally described in regulatory documents as transient, meaning they are temporary and often resolve on their own. The safety profile has been assessed based on repeated use at the standard four-week intervals.

Q: Do I need to change my diet while taking Broadline?

A: According to the official product information, there are no documented restrictions regarding co-administration with food for the target species. The primary post-treatment instruction provided in regulatory documents is to avoid bathing or shampooing the animal for two days following application.

Q: How quickly does Broadline leave the system after the last dose?

A: Pharmacokinetic studies that support the product label provide data on how the drug is processed and eliminated. These studies indicate that the half-life (the time it takes for the amount of drug in the body to be reduced by half) for the main active ingredients is approximately 4 to 6 days.

Q: What is the research evidence for Broadline showing?

A: The research evidence summarized in official indications confirms the product’s authorization for use in treating and preventing mixed infestations. This includes activity against fleas, ticks, tapeworms, and various nematodes (internal roundworms), such as those associated with lungworm and heartworm prevention.

Q: Is it normal to have mild stomach upset when starting Broadline?

A: The official product information notes that if the animal licks the application site after treatment, accidental oral ingestion may occur. This has been reported to uncommonly cause temporary signs of hyper-salivation and vomiting.

Q: Is Broadline safe for people with kidney problems?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The product is for animal treatment only, and the official information does not address human health conditions, such as kidney problems.

Q: Is Broadline safe for people with liver problems?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The product is for animal treatment only, and the official information does not address human health conditions, such as liver problems.

Q: Why does Broadline need a prescription?

A: According to regulatory classification, this product is designated as a veterinary medicinal product subject to prescription. This classification is used by authorities to manage the supply of certain medicines for animal use.

Q: Does Broadline affect my ability to drive or operate machinery?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The official product information does not address human activities, such as driving or operating machinery.

Q: How long can a person stay on Broadline?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The product is not intended for use by human beings, and therefore the official information does not specify a duration of human use.

Q: What should I do if I think I'm having a severe side effect from Broadline?

A: If a person notes any side effects after handling or administering the product, the regulatory package leaflet describes the need to seek immediate medical assistance. Individuals should be prepared to show the physician the package leaflet or the label.

Q: Can Broadline be taken if I have a history of heart issues?

A: The product label includes a specific warning related to heart conditions. It advises that cats in heartworm endemic areas should be tested for existing adult heartworm infestation before being treated with the product for heartworm prevention.

Q: Does Broadline interact with birth control pills?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The official product information does not provide interaction data with human medications such as birth control pills.

Q: Do children or teenagers use Broadline?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The product is not intended for use by children or teenagers.

Q: Are there any specific lifestyle changes recommended while on Broadline?

A: Official warnings state that the animal should not be bathed or shampooed for two days following treatment. Additionally, recently treated animals should not sleep with owners, especially children, until the application site is confirmed to be dry.

Q: What's the typical duration of treatment with Broadline?

A: The standard regimen for continuous management of infestations is defined in official documents as a single application once per month. This interval is designed because one treatment prevents further flea infestations for at least one month.

Q: What are the initial signs that Broadline is working?

A: The first measurable signs of activity are the expected elimination of parasites. The official product indications state that fleas are eliminated within 24 hours after application, and ticks are eliminated within 48 hours.

Q: Can Broadline affect fertility?

A: The regulatory documents state that the safety of the veterinary medicinal product has not been established during pregnancy and lactation in the target species. The regulatory status reflects that use during these periods lacks established safety.

Q: Are there studies on Broadline's use in different racial or ethnic groups?

A: Broadline is a veterinary medicinal product authorized exclusively for use in the feline species. The product information does not contain data on use in human racial or ethnic groups.

Storage & Disposal Map: How to Store and Dispose of Broadline — Official Regulatory Information

Scope Element	Official Regulatory Requirement/Statement
Labeled storage temperature requirements	Store at a temperature below 30 C (86 F).
Light/moisture protection requirements	Must be stored in a dry place and protected from direct heat and sunlight.
Packaging-related storage rules	Must be stored in the original package, including the intact blister.
Child-protection storage requirements	Keep out of the sight and reach of children and out of the reach of uninformed persons and animals.
Disposal instructions	Dispose of unused veterinary medicinal product and waste materials derived from its use according to local requirements.
Environmental disposal requirements	The product is very toxic to aquatic organisms; avoid contamination of any water supply or streams.

Connection to the overall storage/disposal profile: Regulatory documents mandate that the product must be stored below 30 C and protected from light, heat, and moisture to maintain its stability. For safety, it must strictly be kept in the original packaging and out of the reach of children and animals. Used applicators must be disposed of immediately, and due to its aquatic toxicity, all product waste must be handled according to local waste regulations, avoiding all waterways.